Welcome to our dedicated page for Sotera Health Co news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Co stock.
Sotera Health Co (SHC) delivers essential sterilization, lab testing, and advisory services ensuring safety across medical devices, pharmaceuticals, and food production. This page provides investors and industry professionals with timely updates on SHC's operational milestones, regulatory engagements, and strategic initiatives.
Access consolidated news on earnings reports, facility expansions, and technology innovations like gamma irradiation advancements. Track developments across SHC's Sterigenics, Nordion, and Nelson Labs divisions, including partnerships impacting global healthcare safety standards.
Bookmark this page for verified updates on SHC's compliance achievements, leadership changes, and industry contributions. Stay informed through carefully curated press releases and analysis-free reporting tailored for decision-makers in regulated industries.
Sotera Health Company (Nasdaq: SHC) reported Q1 2022 net revenues of $237 million, a 12% increase from Q1 2021. Net income rose to $31 million or $0.11 per share, compared to $11 million or $0.04 per share last year. Adjusted EBITDA reached $115 million, up by 10%. The company reaffirmed its 2022 financial outlook, expecting net revenues between $1.0 billion and $1.03 billion. Despite challenges like the Omicron surge and geopolitical issues, Sotera Health emphasized strong execution and strategic capacity building.
Sotera Health Company (Nasdaq: SHC) plans to release its financial results for Q1 2022 on May 5, 2022, before market open. A conference call to discuss the results will take place at 9:00 a.m. Eastern Time. Participants can join by dialing 1-866-777-2509 from the U.S. or 1-412-317-5413 internationally. A live webcast of the call will be available on the company’s Investor Relations website, with a replay accessible later on the same day.
Sotera Health Company (Nasdaq: SHC) has launched the Sotera Health Academy, a new educational platform offering over 100 hours of curated content aimed at supporting MedTech and Pharmaceutical customers. The Academy features more than 150 resources, including webinars and eBooks, created by industry experts from Nelson Labs, Sterigenics, and Nordion. This initiative follows Sotera's acquisition of Regulatory Compliance Associates, enhancing the platform's offerings. The Academy aims to help manufacturers navigate regulatory risks and accelerate product market entry.
Sotera Health Company (Nasdaq: SHC) reported a strong financial performance for Q4 2021, with net revenues increasing by 11.3% to $241 million and a net income of $36 million, recovering from a loss of $44 million in the previous year. For the full year, revenues rose 13.9% to $931 million, with net income of $117 million compared to a loss of $39 million in 2020. The company expects 2022 revenue growth of 7% to 11% and plans significant investments in capacity expansions. Total debt stood at $1.8 billion with a net leverage ratio of 3.5x as of December 31, 2021.
Nelson Labs has launched the Nelson Labs Mark, a verification program aimed at enhancing transparency in product testing, particularly for face masks and respirators. This initiative addresses the rise of fraudulent products during the ongoing COVID-19 pandemic, providing consumers and institutions with reliable data on product performance. The program includes two-factor authentication for product verification and will expand to include other products as needed. This effort is part of Nelson Labs' mission to safeguard global health.
Sotera Health Company (Nasdaq: SHC) will announce its financial results for Q4 and full year ended December 31, 2021, on March 1, 2022, before market open. The company is a leading provider of sterilization solutions and lab testing services for healthcare. Following the announcement, a conference call will take place at 9:00 a.m. ET to discuss operating highlights and results. Interested participants can access the call via a dedicated phone line or through a live webcast on the company’s Investor Relations website.
Sotera Health Company (NASDAQ: SHC) has provided an update on its growth and achievements during the 40th Annual J.P. Morgan Healthcare Conference. The company expects its full-year 2021 revenues to reach between $920 million and $930 million, reflecting a growth of approximately 14% from the previous year. CEO Michael B. Petras, Jr. emphasized the company's strong execution throughout 2021 and shared insights on its long-term growth strategy and ESG initiatives. Full financial results for Q4 and year-end 2021 will be reported on March 1, 2022.
Sotera Health Company (NASDAQ: SHC) announced that Chairman and CEO Michael B. Petras, Jr. will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 am Eastern. The presentation will provide updates on the company’s diverse businesses focused on end-to-end sterilization solutions and lab testing for healthcare. The management team, including CFO Scott Leffler, will engage in one-on-one meetings with investors. A live webcast can be accessed via the company’s Investor Relations page, and a replay will be available afterward.
Sotera Health Company (Nasdaq: SHC) reported Q3 2021 net revenues of $226 million, up 13.1% from Q3 2020. Net income rose to $27 million or $0.10 per diluted share, compared to $0.01 million in Q3 2020. Adjusted EBITDA increased 16.1% to $117 million, and Adjusted EPS improved to $0.21. Total debt as of September 30, 2021, was $1.78 billion with a net leverage ratio of 3.6x. The company narrowed its full-year revenue outlook to $920 million - $930 million, reflecting 12% - 14% growth.
Sotera Health Company (Nasdaq: SHC) will release its financial results for Q3 and the first nine months of 2021 on November 10, 2021, prior to market open. A conference call will follow at 9:00 a.m. ET to discuss operational highlights and financial results. Participants from the U.S. and Canada can dial 1-833-303-1211, while international attendees can call 1-918-922-6527. A live webcast will be available on the Company’s investor relations website.